Professor Andreas Baumbach

Profile

Professor Andreas Baumbach is active in coronary and structural intervention, and has published extensively in the field of interventional research covering preclinical, first in man, pivotal and post market studies. He has an interest in device innovation and regulatory pathways.

Professor Baumbach has a strong commitment to training and education. He is on the board of directors of the largest interventional congress EuroPCR and PCR London Valves. He is past President of the European Association of Percutaneous Cardiovascular Interventions (EAPCI).

Research

Group members

Prof Christos Bourantas, Dr Anantharam Ramasary, Dr Nida Ahmed, Dr Ratesh Bajaj, Dr Kush Patel

Summary

Active in first in human trials, as well as large scale multinational, multi-centre randomised clinical trial evaluation of novel devices.

Publications

• Wienemann H, Yousefzada S, Rogmann MA et al. (2026). Clinical Outcomes of a Dedicated TAVR Device for Native Aortic Regurgitation: Insights From a Multicenter Real-World Experience.. nameOfConference

  
  

  DOI: 10.1161/circinterventions.126.016851

  
  

  QMRO: qmroHref
• Kanehama N, Wykrzykowska J, Sharif F et al. (2026). PIONEER IV trial: Update in study protocol. nameOfConference

  
  

  DOI: 10.1016/j.ahj.2026.107401

  
  

  QMRO: qmroHref
• Huang J, Tu S, Huang H et al. (publicationYear). Radial wall strain for residual risk stratification after percutaneous coronary intervention.. nameOfConference

  
  

  DOI: 10.4244/eij-d-26-00126

  
  

  QMRO: qmroHref
• Ktenopoulos N, Apostolos A, Terentes-Printzios D et al. (2026). Redo-Transcatheter Aortic Valve Implantation Versus Surgical Explantation in Patients With Previous Transcatheter Aortic Valve Implantation: A Systematic Review and Meta-Analysis.. nameOfConference

  
  

  DOI: 10.1161/jaha.125.048885

  
  

  QMRO: qmroHref
• Tobe A, Onuma Y, van Royen N et al. (2026). Impact of Early Nonfatal Complications After Transcatheter Aortic Valve Implantation on 1-Year Mortality and Quality of Life: Insights From the LANDMARK Trial. nameOfConference

  
  

  DOI: 10.1016/j.shj.2026.101101

  
  

  QMRO: qmroHref
• Torii R, Mohammed A, Gamrah MA et al. (publicationYear). Realistic anatomical model reconstruction and high-fidelity flow computation in stented coronary arteries for the analysis of in-stent thrombosis. nameOfConference

  
  

  DOI: 10.3389/fcvm.2026.1863952

  
  

  QMRO: qmroHref
• Bajaj R, Wan MYS, Thielemans K et al. (publicationYear). From incidental positron emission uptake to in-vivo phenotyping: a short history of positron emission tomography in the study of atherosclerosis and the vulnerable plaque. nameOfConference

  
  

  DOI: 10.3389/fcvm.2026.1767077

  
  

  QMRO: qmroHref
• Gierlich T, Baumbach A, Kungl AF et al. (publicationYear). Spike-based alignment learning solves the weight transport problem. nameOfConference

  
  

  DOI: 10.1038/s41467-026-74460-8

  
  

  QMRO: qmroHref
• Tobe A, Onuma Y, van Royen N et al. (2026). Effective orifice area after Myval and SAPIEN transcatheter valve implantation stratified by flow status: insights from the LANDMARK trial. nameOfConference

  
  

  DOI: 10.1016/j.ijcha.2026.101966

  
  

  QMRO: qmroHref
• Smits P, Rampat R, van Royen N et al. (2026). 83204 | Predictors of Conduction System Disturbances Resulting in a New Permanent Pacemaker Implantation: A Sub-study of the LANDMARK Trial. nameOfConference

  
  

  DOI: 10.1016/j.shj.2026.100967

  
  

  QMRO: qmroHref

Collaborators

External

• Meril Life
• Jenavalve
• Microport

Disclosures

• Institutional Research Support: Abbott Vascular
• Consultation and Speaker Fees: Astra Zeneca, Sinomed, Microport, Medtronic, Faraday Pi-Cardia, Biosensors, Jenavalve